Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity.

Garrido G, Schrand B, Rabasa A, Levay A, D'Eramo F, Berezhnoy A, Modi S, Gefen T, Marijt K, Doorduijn E, Dudeja V, van Hall T, Gilboa E.

Nat Commun. 2019 Aug 21;10(1):3773. doi: 10.1038/s41467-019-11728-2.

2.

TEIPP peptides: exploration of unTAPped cancer antigens.

Marijt KA, Van Der Burg SH, van Hall T.

Oncoimmunology. 2019 May 13;8(8):1599639. doi: 10.1080/2162402X.2019.1599639. eCollection 2019.

3.

Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?

van Weeghel C, Wierenga APA, Versluis M, van Hall T, van der Velden PA, Kroes WGM, Pfeffer U, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1127. doi: 10.3390/cancers11081127.

4.

Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.

Marijt KA, Sluijter M, Blijleven L, Tolmeijer SH, Scheeren FA, van der Burg SH, van Hall T.

J Immunother Cancer. 2019 Jun 13;7(1):152. doi: 10.1186/s40425-019-0627-8.

5.

A herpesvirus encoded Qa-1 mimic inhibits natural killer cell cytotoxicity through CD94/NKG2A receptor engagement.

Wang X, Piersma SJ, Nelson CA, Dai YN, Christensen T, Lazear E, Yang L, Sluijter M, van Hall T, Hansen TH, Yokoyama WM, Fremont DH.

Elife. 2018 Dec 21;7. pii: e38667. doi: 10.7554/eLife.38667.

6.

Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.

Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F.

JCI Insight. 2018 Dec 6;3(23). pii: 124507. doi: 10.1172/jci.insight.124507.

7.

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T.

Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29.

PMID:
30503208
8.

Arming oncolytic reovirus with GM-CSF gene to enhance immunity.

Kemp V, van den Wollenberg DJM, Camps MGM, van Hall T, Kinderman P, Pronk-van Montfoort N, Hoeben RC.

Cancer Gene Ther. 2019 Sep;26(9-10):268-281. doi: 10.1038/s41417-018-0063-9. Epub 2018 Nov 23.

PMID:
30467340
9.

High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.

Benonisson H, Sow HS, Breukel C, Claassens J, Brouwers C, Linssen MM, Fransen MF, Sluijter M, Ossendorp F, van Hall T, Verbeek JS.

J Immunol. 2018 Dec 15;201(12):3741-3749. doi: 10.4049/jimmunol.1800700. Epub 2018 Nov 5.

PMID:
30397036
10.

CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.

Benonisson H, Altıntaş I, Sluijter M, Verploegen S, Labrijn AF, Schuurhuis DH, Houtkamp MA, Verbeek JS, Schuurman J, van Hall T.

Mol Cancer Ther. 2019 Feb;18(2):312-322. doi: 10.1158/1535-7163.MCT-18-0679. Epub 2018 Oct 31.

PMID:
30381448
11.

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.

Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS.

Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12.

PMID:
30259976
12.

Identification of non-mutated neoantigens presented by TAP-deficient tumors.

Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T.

J Exp Med. 2018 Sep 3;215(9):2325-2337. doi: 10.1084/jem.20180577. Epub 2018 Aug 16.

13.

Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange MJ, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GPM, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Dec;16(12):1902-1911. doi: 10.1158/1541-7786.MCR-18-0114. Epub 2018 Aug 9.

PMID:
30093564
14.

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

Benonisson H, Sow HS, Breukel C, Claassens JWC, Brouwers C, Linssen MM, Redeker A, Fransen MF, van Hall T, Ossendorp F, Arens R, Verbeek S.

Oncotarget. 2018 Jun 29;9(50):29392-29402. doi: 10.18632/oncotarget.25630. eCollection 2018 Jun 29.

15.

TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers.

Marijt KA, Doorduijn EM, van Hall T.

Mol Immunol. 2019 Sep;113:43-49. doi: 10.1016/j.molimm.2018.03.029. Epub 2018 Apr 4.

16.

A Restricted Role for FcγR in the Regulation of Adaptive Immunity.

Fransen MF, Benonisson H, van Maren WW, Sow HS, Breukel C, Linssen MM, Claassens JWC, Brouwers C, van der Kaa J, Camps M, Kleinovink JW, Vonk KK, van Heiningen S, Klar N, van Beek L, van Harmelen V, Daxinger L, Nandakumar KS, Holmdahl R, Coward C, Lin Q, Hirose S, Salvatori D, van Hall T, van Kooten C, Mastroeni P, Ossendorp F, Verbeek JS.

J Immunol. 2018 Apr 15;200(8):2615-2626. doi: 10.4049/jimmunol.1700429. Epub 2018 Mar 9.

17.

The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.

Hafstrand I, Doorduijn EM, Sun R, Talyzina A, Sluijter M, Pellegrino S, Sandalova T, Duru AD, van Hall T, Achour A.

J Immunol. 2018 Apr 15;200(8):2860-2868. doi: 10.4049/jimmunol.1700228. Epub 2018 Mar 5.

18.

T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant Lymphocytes.

Doorduijn EM, Sluijter M, Querido BJ, Seidel UJE, Oliveira CC, van der Burg SH, van Hall T.

Front Immunol. 2018 Jan 25;9:60. doi: 10.3389/fimmu.2018.00060. eCollection 2018.

19.

T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.

Doorduijn EM, Sluijter M, Marijt KA, Querido BJ, van der Burg SH, van Hall T.

Oncoimmunology. 2017 Nov 20;7(3):e1382793. doi: 10.1080/2162402X.2017.1382793. eCollection 2018.

20.

PD-L1 immune suppression in cancer: Tumor cells or host cells?

Kleinovink JW, van Hall T, Ossendorp F, Fransen MF.

Oncoimmunology. 2017 May 12;6(7):e1325982. doi: 10.1080/2162402X.2017.1325982. eCollection 2017.

Supplemental Content

Loading ...
Support Center